<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04287777</url>
  </required_header>
  <id_info>
    <org_study_id>RJ-NBC01</org_study_id>
    <nct_id>NCT04287777</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Mupirocin Gel in Children With Impetigo</brief_title>
  <official_title>Ph-III Randomized, Multicentric, Controlled , Non-inferiority Trial to Evaluate the Safety and Efficacy of Mupirocin Gel 20 mg/g Versus Mupirocin Ointment 20 mg/g and Placebo in the Treatment of Impetigo in Paediatric Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reig Jofre Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reig Jofre Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to show non inferiority in terms of safety and efficacy of
      topical administration BID of Mupirocin Gel 20 mg/g compared to topical administration of
      Mupirocin Ointment 20 mg/g TID (Bactroban) in the treatment of impetigo in paediatric
      population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical cure at the end of treatment by SIRS assessed by blind observer</measure>
    <time_frame>Day 8</time_frame>
    <description>Proportion of subjects with clinical cure at the Day 8 visit, assessed by blind observer, according to criteria described in the Protocol (SIRS &lt; or = 2).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical cure as assessed by the proportion of subjects with no additional antibiotic therapy required to treat impétigo at day 8</measure>
    <time_frame>Day 8</time_frame>
    <description>proportion of subjects with no additional antibiotic therapy required to treat impetigo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical cure at the end of follow up by SIRS assessed by blind observer</measure>
    <time_frame>Day14</time_frame>
    <description>Proportion of subjects with clinical cure at the Day 14 visit, assessed by blind observer, according to criteria described in the protocol (SIRS &lt; or = 2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical cure as assessed by the proportion of subjects with no additional antibiotic therapy required to treat impétigo at day 14</measure>
    <time_frame>Day14</time_frame>
    <description>proportionof subjects with no additional antibiotic therapy required to treat impetigo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total SIRS score at the end of treatment and follow-up by blind observer</measure>
    <time_frame>Day 8 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacteriology cure at follow-up</measure>
    <time_frame>Day 14</time_frame>
    <description>Bacteriology eradication at the end of follow-up period according to culture at screening and follow up visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical cure at the end of treatment and follow-up by investigator</measure>
    <time_frame>Day 8 and 14</time_frame>
    <description>Proportion of subjects with clinical cure at the Day 8 and Day 14 visits, assessed by investigator, according to protocol criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SIRS total score at the end of treatment and follow-up by investigator</measure>
    <time_frame>Day 8 and 14</time_frame>
    <description>SIRS total Score at Day 8 and Day 14 visits, assessed by the investigator</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">467</enrollment>
  <condition>Impetigo</condition>
  <arm_group>
    <arm_group_label>Mupirocin gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical administration of Mupirocin gel 20 mg/g BID for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mupirocin ointment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical administration of Mupirocin ointment 20mg/g TID for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical administration of Placebo (ointment) TID for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mupirocin gel</intervention_name>
    <description>Topical administration of Mupirocin gel 20 mg/g BID for 7 days</description>
    <arm_group_label>Mupirocin gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mupirocin ointment</intervention_name>
    <description>Topical treatment of Mupirocin ointment 20 mg/g TID for 7 days</description>
    <arm_group_label>Mupirocin ointment</arm_group_label>
    <other_name>Bactroban</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Topical administration of Placebo (ointment) TID during 7 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 months and 15 years at the signature of informed consent

          -  Impetigo susceptible to be treated with topical mupirocin and non requiring systemic
             antibiotic treatment (maximum of 4 different affected areas and no fever).

          -  Global score of Skin Infection Rating Scale (SIRS) ≥ 4, with positive value (≥ 1) in
             at least 3 of the 5 categories evaluated.

          -  Signature of informed consent by parent or legal tutor and, in case of mature minor
             (12 years or more), signature of informed assent.

          -  Patient or parent's ability to understand and fulfill with protocol requirements.

          -  In potentially pregnant patients, negative pregnancy urine test at baseline and use of
             reliable contraception double barrier methods during the trial.

        Exclusion Criteria:

          -  Allergy to any compound of the trial treatments

          -  Have received systemic treatment with antibiotics or steroids, during the week prior
             to the baseline visit.

          -  Have received topical treatment with corticosteroids, antibiotics or antifungals,
             during the 48 hours prior to the baseline visit.

          -  Primary or secondary immunodeficiency.

          -  Have received cytostatic or immunosuppressive treatment three months prior to
             baseline.

          -  Any skin disorder that could interfere with the evaluation of the results of impetigo,
             such as presence of staphylococcal or streptococcal ecthyma, cellulitis, furunculosis,
             acute dermatitis, contact dermatitis or impetiginized eczema.

          -  Diabetes mellitus.

          -  Infection that, in the investigator's opinion, should be treated with systemic
             antibiotic.

          -  Any medical condition which, in the investigator's opinion, contraindicates the
             subject's participation in the trial.

          -  Forecast of little cooperation, non-compliance with medical treatment or low
             credibility.

          -  Have participated in any clinical investigation with medicine within 30 days prior to
             basal visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raúl De Lucas, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Hospital La Paz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CAP Torreblanca</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP La Algaba</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41980</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP Vallcarca-St. Gervasi</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <zip>08023</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP Corbera de Llobregat</name>
      <address>
        <city>Corbera De Llobregat</city>
        <state>Catalonia</state>
        <zip>08757</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP Amadeu Torner</name>
      <address>
        <city>L'Hospitalet De Llobregat</city>
        <state>Catalonia</state>
        <zip>08902</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP Mossèn Cinto Verdager</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Catalonia</state>
        <zip>08902</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP Florida Nord</name>
      <address>
        <city>L'HOspitalet de Llobregat</city>
        <state>Catalonia</state>
        <zip>08905</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP Rambla Ferran</name>
      <address>
        <city>Lleida</city>
        <state>Catalonia</state>
        <zip>25007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP Maria Bernades</name>
      <address>
        <city>Viladecans</city>
        <state>Catalonia</state>
        <zip>08840</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.U. Sureste</name>
      <address>
        <city>Arganda del Rey</city>
        <state>Madrid</state>
        <zip>28500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.U. Fuenlabrada</name>
      <address>
        <city>Fuenlabrada</city>
        <state>Madrid</state>
        <zip>21942</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP Castilla la Nueva</name>
      <address>
        <city>Fuenlabrada</city>
        <state>Madrid</state>
        <zip>28945</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP Pinto</name>
      <address>
        <city>Pinto</city>
        <state>Madrid</state>
        <zip>28320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP Pozuelo de Alarcón</name>
      <address>
        <city>Pozuelo de Alarcón</city>
        <state>Madrid</state>
        <zip>28224</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.U. Infanta Sofía</name>
      <address>
        <city>San Sebastián de los Reyes</city>
        <state>Madrid</state>
        <zip>28702</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP Cea Bermúdez</name>
      <address>
        <city>Madrid</city>
        <zip>28003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio MArañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP Campo de la Paloma</name>
      <address>
        <city>Madrid</city>
        <zip>28018</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP Aravaca</name>
      <address>
        <city>Madrid</city>
        <zip>28023</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP La Calesas</name>
      <address>
        <city>Madrid</city>
        <zip>28026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 29, 2015</study_first_submitted>
  <study_first_submitted_qc>February 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2020</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Impetigo</keyword>
  <keyword>Mupirocin</keyword>
  <keyword>Mupirocin gel</keyword>
  <keyword>Mupirocin ointment</keyword>
  <keyword>Impetigo in children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Impetigo</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mupirocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

